STT

----

Recursion Pharmaceuticals (RXRX) 的最新股权结构

I'm LongbridgeAI, I can summarize articles.

$Recursion Pharmaceuticals(RXRX.US)’s equity structure exhibits three distinctive characteristics: **"Backed by AI giants, crowded with renowned growth funds, and regular insider selling by the founder."**

As of the latest data in December 2025, here is a detailed summary of RXRX’s institutional and core team holdings:

1. Institutional Ownership Overview

Institutional investors currently hold approximately 60% - 70% of RXRX’s outstanding shares. Unlike traditional pharmaceutical companies, RXRX’s shareholder list is dominated by aggressive funds with strong "tech/AI" characteristics.

Top Institutional Holders

Institution	Ownership (Approx.)	Style	Recent Moves (2025 Q3-Q4)
Vanguard Group	7.6% - 9.2%	Passive/Index	Increased holdings. The largest institutional shareholder, primarily through healthcare and total market ETFs.
ARK Investment (Cathie Wood)	6.5% - 7.5%	Aggressive Growth	Core holding. RXRX is one of "Cathie Wood’s" flagship positions in AI biotech, and ARK remains one of its most steadfast bulls.
BlackRock	6.1%	Passive/Index	Increased holdings. Passive fund allocations continue to rise amid RXRX’s market cap fluctuations.
Baillie Gifford	4.6%	Long-Term Growth	Reduced/Adjusted. As an early backer of Tesla, BG has held RXRX long-term but recently engaged in position management with slight reductions.
State Street	3.5%	Passive/Index	Significantly increased holdings. Recent data shows a 60%+ rise in its position, reflecting strong allocation demand.

2. Strategic & Sovereign Holders

These shareholders represent RXRX’s uniqueness, featuring global tech giants and sovereign wealth funds that strongly endorse its "TechBio" narrative.

NVIDIA: Top strategic shareholder.

Holds approximately 7.7 million shares.

Significance: NVIDIA announced a $50 million investment in 2023, marking RXRX’s standout advantage over other biotech firms. This is not just a financial investment but a deep collaboration in computing power and AI models.

Softbank Group: Holds about 14.6 million shares (~2.8%), reinforcing RXRX’s AI tech credentials.

Kinnevik AB: Holds ~13.4 million shares. A prominent Swedish investment firm with long-term support for digital healthcare.

Mubadala Investment (Abu Dhabi sovereign fund): Holds ~13 million shares, representing heavy Middle Eastern capital exposure.

3. Core Team & Insiders

As of end-2025, insiders hold ~13% of shares. The most notable trend is the consistent, scheduled selling by key executives.

Key Figure: Chris Gibson (Co-Founder & CEO)

Ownership status: Remains one of the largest individual shareholders, directly holding nearly 1 million shares, with additional indirect holdings via family trusts and LLCs.

Recent moves: Frequent selling.

H2 2025: Executed an intensive selling plan (Rule 10b5-1), e.g., 40,000 shares each on Dec 4, Nov 19, and Nov 4.

Block trade: Sold over 500,000 shares in a single transaction in August 2025.

Interpretation: This "drip-feed" selling is typically for personal financial diversification but is seen as a short-term bearish signal amid low stock prices.

Other Executives & Directors

Blake Borgeson (Co-Founder/Director): Sold 220,000 shares in Dec 2025, a significant reduction.

Najat Khan (Chief R&D/Commercial Officer): Minor selling in November.

Lux Ventures: Early VC, still holds ~30 million shares (~5.8%), a long-term insider.

Summary & Insights

Strong backing vs. insider selling: RXRX boasts the most prestigious shareholder roster in biotech (NVIDIA + ARK + Softbank + BlackRock), providing strong downside support and narrative value. However, the CEO and co-founder’s persistent selling (albeit planned) somewhat caps upside potential.

Focus areas:

NVIDIA’s stance: As long as NVIDIA holds, RXRX’s "AI pharma leader" status remains intact.

ARK’s position: Cathie Wood’s fund continues to add/hold, signaling confidence in RXRX’s long-term tech roadmap.

Cash flow: Given insider selling, markets will watch for potential equity dilution to fund high AI computing costs.

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.